Deep Track Capital discloses 5.13% Ocular Therapeutix (OCUL) ownership stake

Rhea-AI Filing Summary

Deep Track Capital and affiliates report a significant ownership stake in Ocular Therapeutix, Inc. They beneficially own 11,234,132 shares of common stock, representing 5.13% of the company as of February 10, 2026.

The position is held through Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and individual reporting person David Kroin, who share dispositive power over the same 11,234,132 shares. This amount includes 1,163,718 pre-funded warrants that are exercisable into common stock, subject to a 9.99% “Maximum Percentage” limitation on beneficial ownership after exercise.

The ownership percentage is calculated using 218,855,497 shares, combining 217,691,779 shares outstanding as of February 2, 2026 and the shares underlying the pre-funded warrants. The filers certify that the securities are not held for the purpose of changing or influencing control of Ocular Therapeutix.

Insights

Equity ownership & governance analyst

Deep Track discloses a 5.13% passive stake in Ocular Therapeutix.

Deep Track Capital, its biotech master fund, and David Kroin collectively report beneficial ownership of 11,234,132 Ocular Therapeutix common shares, equal to 5.13% of the company based on 218,855,497 calculated shares as of February 10, 2026.

The position includes 1,163,718 pre-funded warrants exercisable into common stock, but subject to a 9.99% beneficial ownership cap. This cap limits how many warrants can be exercised at once so that ownership does not exceed 9.99% of outstanding shares immediately after exercise.

The filers certify the holdings are not for changing or influencing control, aligning this with a passive investment under Schedule 13G. Future ownership levels will depend on any warrant exercises and changes in Ocular’s outstanding share count disclosed in later company filings.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Ocular Therapeutix, Inc

(Name of Issuer)

Common Stock, $0.0001 par value per share

(Title of Class of Securities)

67576A100

(CUSIP Number)

02/05/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 67576A100

1

Names of Reporting Persons

Deep Track Capital, LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 11,234,132.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

11,234,132.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.13 %

12

Type of Reporting Person (See Instructions)

IA, OO

SCHEDULE 13G

CUSIP No. 67576A100

1

Names of Reporting Persons

Deep Track Biotechnology Master Fund, Ltd.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 11,234,132.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 11,234,132.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

11,234,132.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.13 %

12

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13G

CUSIP No. 67576A100

1

Names of Reporting Persons

David Kroin

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 11,234,132.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 11,234,132.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

11,234,132.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.13 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Ocular Therapeutix, Inc
(b)	Address of issuer's principal executive offices: 15 Crosby Drive, Bedford, MA 01730
Item 2.
(a)	Name of person filing: (i) Deep Track Capital, LP (ii) Deep Track Biotechnology Master Fund, Ltd. (iii) David Kroin
(b)	Address or principal business office or, if none, residence: (i) 200 Greenwich Ave, 3rd Floor, Greenwich, CT 06830 (ii) c/o Walkers Corporate Limited, 190 Elgin Ave, George Town, KY1-9001, Cayman Islands (iii) c/o Deep Track Capital, LP, 200 Greenwich Ave, 3rd Floor, Greenwich, CT 06830
(c)	Citizenship: (i) Delaware (ii) Cayman Islands (iii) United States
(d)	Title of class of securities: Common Stock, $0.0001 par value per share
(e)	CUSIP No.: 67576A100
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 11,234,132
(b)	Percent of class: 5.13%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 11,234,132
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. Deep Track Capital, LP is the relevant entity for which David Kroin may be considered a control person.
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Deep Track Capital, LP

Signature:	/s/ David Kroin
Name/Title:	David Kroin, Managing Member of the General Partner of the Investment Adviser
Date:	02/10/2026

Deep Track Biotechnology Master Fund, Ltd.

Signature:	/s/ David Kroin
Name/Title:	David Kroin, Director
Date:	02/10/2026

David Kroin

Signature:	/s/ David Kroin
Name/Title:	David Kroin
Date:	02/10/2026

Exhibit Information

Item 4: Information with respect to the Reporting Persons' ownership of the Common Stock as of February 10, 2026, is incorporated by reference to items (5) - (9) and (11) of the cover page of the respective Reporting Person. The amount beneficially owned by each Reporting Person is determined using 218,855,497 shares, calculated using 217,691,779 Common Stock outstanding as of February 2, 2026, according to the issuer's 10-K filed with the SEC on February 5, 2026 and 1,163,718 Common Stock that would be converted to Common Stock by the Reporting Person up to the Maximum Percentage. The beneficially owned shares include 1,163,718 Pre-Funded Warrants exercisable to common shares, subject to a 9.99% Maximum Percentage exercise limitation. The Issuer shall not effect the exercise of any portion of the Pre-Funded Warrants, to the extent that after giving effect to such exercise, the holder collectively would beneficially own in excess of 9.99% (the "Maximum Percentage") of the number of Common Stock outstanding immediately after giving effect to such exercise. JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on SCHEDULE 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on SCHEDULE 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. Dated: February 10, 2026 Deep Track Capital, LP By: /s/ David Kroin David Kroin, Managing Member of the General Partner of the Investment Adviser Deep Track Biotechnology Master Fund, Ltd. By: /s/ David Kroin David Kroin, Director David Kroin By: /s/ David Kroin David Kroin

FAQ

How much of Ocular Therapeutix (OCUL) does Deep Track Capital own?

Deep Track Capital and its affiliates beneficially own 11,234,132 shares of Ocular Therapeutix common stock, representing 5.13% of the company. This percentage is based on 218,855,497 shares, including outstanding stock and shares underlying pre-funded warrants.

Who are the reporting persons in the Ocular Therapeutix (OCUL) Schedule 13G?

The Schedule 13G lists three reporting persons: Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin. They report shared dispositive power over the same 11,234,132 Ocular Therapeutix common shares.

What role do pre-funded warrants play in Deep Track’s OCUL ownership?

Deep Track’s beneficial ownership includes 1,163,718 pre-funded warrants, exercisable into Ocular Therapeutix common stock. These warrants are subject to a 9.99% Maximum Percentage limit, restricting exercises that would push post-exercise ownership above 9.99% of outstanding shares.

How was Deep Track’s 5.13% ownership in Ocular Therapeutix (OCUL) calculated?

The 5.13% figure uses a base of 218,855,497 shares, combining 217,691,779 common shares outstanding as of February 2, 2026 and 1,163,718 shares issuable from pre-funded warrants, all as described in the Schedule 13G disclosure.

Is Deep Track Capital seeking control of Ocular Therapeutix (OCUL)?

The reporting persons certify the Ocular Therapeutix securities were not acquired to change or influence control of the company. They also state the holdings are not part of any transaction aimed at obtaining control, consistent with a passive Schedule 13G filing.

What voting and dispositive powers does Deep Track have over OCUL shares?

The Schedule 13G reports no sole voting or dispositive power for any filer, and 11,234,132 shares with shared dispositive power. Shared voting power is disclosed as zero, indicating coordinated authority over disposition but not over shareholder voting.